EQ101 Phase 2 Study

Disease: Alopecia Areata

A Phase 2 multicenter, open-label, proof-of-concept study in subjects with moderate, severe and very severe alopecia areata (AA).

EQ101 Phase 2 Study

Trial Overview

This is a Phase 2 multicenter, open-label, proof-of-concept study in approximately 30 adult subjects between 18 and 60 years of age, with at least 35% scalp hair loss due to alopecia areata (AA). Subjects will be dosed intravenously once weekly for 24 weeks with EQ101 at a dose level of 2 mg/kg, and subsequently followed for an additional four weeks. The primary objective of the study is to evaluate the safety and tolerability of EQ101 in subjects with moderate to severe AA over a 24-week treatment period; secondary objectives will be to evaluate drug efficacy, pharmacokinetic/pharmacodynamic (PK/PD) properties, and to assess changes in patient biomarkers.


Clinical Study Overview Disease Info »